Every Form 4 that Apogee Therapeutics Inc (APGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APGE filings page.
Apogee Therapeutics, Inc. (APGE) reports that investment entities associated with Fairmount Funds and related directors disposed of their holdings in connection with a merger under which AbbVie Inc. is acquiring Apogee. All reported common and non-voting common shares, including 6,743,321 shares of non-voting common stock and 340,855 shares of common stock held through Fairmount Healthcare Fund II L.P., were transferred to the acquirer’s merger vehicle in exchange for cash of $135.11 per share. Vested stock options held for Fairmount-managed vehicles were also canceled for cash equal to $135.11 minus the applicable exercise price, and the Fairmount parties and the named individuals disclaim beneficial ownership except to the extent of any pecuniary interest.
Apogee Therapeutics, Inc. (APGE) director Mark C. McKenna reported dispositions of company securities in connection with a merger. On September 3, 2026, he returned vested stock options covering 150,000, 10,370, 14,461 and 7,657 shares of common stock to the issuer, with exercise prices of $23.60, $43.85, $41.66 and $85.00, respectively. Each option was cashed out under an Agreement and Plan of Merger at $135.11 per share of merger consideration, reduced by the relevant exercise price. In a related transaction, 20,000 shares of common stock were also disposed of pursuant to the same merger agreement, and his directly held common stock position became 0 shares after the transaction. The filing states that these options were vested or became fully vested in connection with the merger and that no Rule 10b5-1 trading plan is reported.
Apogee Therapeutics, Inc. (APGE) director William A. Jones Jr. reported the disposition of company equity in connection with a merger under an Agreement and Plan of Merger among Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc. and AbbVie Inc. on September 3, 2026.
Jones disposed of 34,824 shares of common stock and three blocks of vested stock options covering 10,370, 14,461 and 7,657 shares. Each option was cashed out for the cash value of the per share merger consideration of $135.11 minus its exercise price, and Jones reported holding no shares of common stock directly after the transactions. No Rule 10b5-1 plan is reported.
Apogee Therapeutics, Inc. (APGE) reports that Chief Medical Officer Carl Dambkowski disposed of common stock and stock options in early September 2026, primarily in connection with the cash merger of Apogee with an AbbVie Inc.–affiliated entity under an Agreement and Plan of Merger.
Apogee Therapeutics, Inc. (APGE) reports that director Jennifer A. Fox disposed of her equity position in connection with a merger. On September 3, 2026, she transferred 34,824 shares of common stock to the company under an Agreement and Plan of Merger involving AbbVie Inc. and related entities, leaving her with no directly held common shares.
On the same date, three vested stock option awards covering 10,370 shares at an exercise price of $43.85, 14,461 shares at $41.66, and 7,657 shares at $85.00 were also disposed of to the issuer. Each option was cashed out for an amount equal to the $135.11 per share merger consideration minus the respective exercise price, consistent with the merger terms. No Rule 10b5-1 trading plan is reported for these transactions.
Apogee Therapeutics, Inc. (APGE) reported that Chief Financial Officer Jane Henderson disposed of company equity on September 3, 2026 in connection with a merger under an Agreement and Plan of Merger among Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc. and AbbVie Inc. The transactions included the disposition of 158,371 shares of common stock, after which she held no shares of common stock directly. Three vested stock option awards covering 175,345, 124,962 and 83,690 underlying shares, with exercise prices of $22.86, $49.07 and $75.78 per share, respectively, were also disposed of in connection with the merger. Each option was cashed out for an amount equal to the excess of the $135.11 per share merger consideration over its exercise price, rather than exercised for shares. The options were vested as of, or became fully vested in connection with, the merger, and the filing does not state that these transactions were made under a Rule 10b5-1 trading plan.
Apogee Therapeutics, Inc. (APGE) director Lisa Bollinger reported the disposition to the issuer of four tranches of vested stock options on September 3, 2026 in connection with a merger. Options covering 18,550, 8,112, 14,461 and 7,657 shares of common stock, with exercise prices of $47.86, $43.85, $41.66 and $85.00 respectively, were canceled pursuant to an Agreement and Plan of Merger dated June 18, 2026. Each option was exchanged for a cash payment equal to the merger consideration of $135.11 minus its exercise price, and the filing states these options were vested or became fully vested in connection with the merger. No Rule 10b5-1 trading plan is reported.
Apogee Therapeutics, Inc. (APGE) reports that Chief Executive Officer and director Michael Thomas Henderson disposed of his equity interests in connection with a merger involving Andor LLC, Andor Merger Co. and AbbVie Inc. On September 3, 2026, he returned 920,941 shares of common stock to the issuer under the merger terms and three fully vested option grants were canceled in exchange for cash equal to the $135.11 per share merger consideration minus each option’s exercise price. No Rule 10b5-1 trading plan is reported for these transactions.
Apogee Therapeutics, Inc. (APGE) director Nimish P. Shah reported multiple dispositions of equity interests on September 3, 2026, all made in connection with the acquisition of Apogee by AbbVie Inc. Venrock-affiliated funds and entities associated with Shah exchanged common stock, Non-Voting Common Stock, stock options and pre-funded warrants for cash based on $135.11 per share merger consideration, including options where the cash paid equaled $135.11 minus the option exercise price. The filing states that Shah and the relevant Venrock management entities disclaim beneficial ownership of the fund-held securities except for their indirect pecuniary interests, and that the reported fund and warrant positions and Non-Voting Common Stock holdings are reduced to zero following these transactions.
Apogee Therapeutics, Inc. reported option exercises and related share movements involving Fairmount-affiliated entities. On 2026-08-07, options to acquire 31,838 and 10,370 shares of common stock were exercised at strike prices of $17.00 and $43.85 per share, respectively. The resulting common shares are held indirectly through Fairmount Healthcare Fund II L.P., with 51,166 shares reported as indirectly held for each of Tomas Kiselak and Peter Harwin, who, along with Fairmount, disclaim beneficial ownership except to the extent of their pecuniary interest.
Apogee Therapeutics’ Chief Medical Officer Carl Dambkowski exercised stock options for 4,125 shares of common stock at $22.8600 per share on August 5, 2026, and on the same date sold 5,500 shares at $134.1700 per share under a Rule 10b5-1 trading plan. After the option exercise, 110,665 option shares from this award remained outstanding; the option originally covered 175,345 shares vesting in 48 equal monthly installments through December 18, 2027.
Apogee Therapeutics Chief Financial Officer Jane Henderson reported a bona fide gift of 15,000 shares of common stock to a donor-advised fund. After this transfer, she directly holds 158,371 shares. The transaction was reported as not made under a Rule 10b5-1 plan.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported a bona fide gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund, a non-market disposition recorded at $0.00 per share.
Following the gift, Dambkowski directly holds 169,873 shares of Apogee common stock. No open-market purchases or sales were reported in this insider transaction.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson reported two stock transactions. On July 8, he sold 20,000 shares of common stock in an open-market transaction at a weighted average price of $133.63 per share under a pre-arranged Rule 10b5-1 trading plan. On July 10, he made a bona fide gift of 75,046 shares of common stock to a donor advised fund. Following these transactions, he held 920,941 shares of Apogee common stock directly.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an option exercise and related share sale in company stock. He exercised stock options covering 4,125 shares of common stock at a price of $22.86 per share and sold 5,500 shares of common stock in an open-market transaction at an average price of $132.74 per share.
Following these transactions, Dambkowski directly owns 177,873 shares of common stock and holds stock options representing 114,790 shares after the partial exercise. The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an open-market sale of 26,400 shares of Common Stock on June 22, 2026 at a weighted average price of $132.60 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. After this sale, he directly holds 179,248 shares of Apogee Therapeutics Common Stock.
Apogee Therapeutics, Inc. director and Chief Executive Officer Michael Thomas Henderson reported an open-market sale of 80,000 shares of Common Stock at a weighted average price of $132.54 per share. Following the transaction, he directly holds 1,015,987 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson reported multiple open-market sales of common stock. On June 10, 2026, he sold a total of 20,000 shares of Apogee common stock in several transactions under a previously adopted Rule 10b5-1 trading plan dated August 13, 2025. Reported sale prices for these trades include individual weighted-average prices such as $82.78 and $86.89 per share, with underlying trade ranges detailed in the footnotes. Following these sales, Henderson continued to directly own 1,095,987 shares of Apogee common stock.
Apogee Therapeutics, Inc. reported a routine equity compensation grant linked to director Tomas Kiselak and Fairmount Funds Management LLC. A stock option was awarded representing the right to buy 7,657 shares of common stock at an exercise price of $85.00 per share.
The option vests on the one-year anniversary of the grant date, conditioned on Mr. Kiselak’s continued service. According to the footnotes, he holds the option for one or more investment vehicles managed by Fairmount, must deliver any net cash or stock to Fairmount, and therefore disclaims beneficial ownership, while Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Apogee Therapeutics director Nimish P. Shah reported a grant of stock options covering 7,657 shares of common stock, with an exercise price of 85.00 and expiration on 2036-06-09. The options vest on the one-year anniversary of the 2026-06-09 grant date.
Under an agreement, the option and underlying shares are held for the sole benefit of Venrock Management, LLC, which directs any exercise and is entitled to the shares. Shah may be deemed an indirect beneficial owner only to the extent of his pecuniary interest.
Apogee Therapeutics director Mark C. McKenna received a grant of stock options covering 7,657 shares of common stock at an exercise price of $85.00 per share. The options vest on the one-year anniversary of the June 9, 2026 grant date, contingent on his continued service, and expire on June 9, 2036.
Apogee Therapeutics director William A. Jones Jr received a grant of stock options giving him the right to buy 7,657 shares of Apogee common stock at an exercise price of $85.0000 per share. These options were awarded as compensation, not purchased in the open market, and expire on June 9, 2036. The award will fully vest on the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. After this grant, he directly holds options covering 7,657 underlying shares.
Apogee Therapeutics director Jennifer A. Fox received a new stock option grant. She was awarded options to buy 7,657 shares of common stock at an exercise price of $85.0000 per share. The option vests on the one-year anniversary of the grant date and expires on June 9, 2036, reflecting a compensation-related award rather than an open-market purchase or sale.
Apogee Therapeutics director Lisa Bollinger received a stock option grant for 7,657 shares of common stock on June 9, 2026. The option has an exercise price of $85.00 per share and expires on June 9, 2036. All 7,657 options will vest on the one-year anniversary of the grant date, contingent on her continued service, and represent her total option holdings reported in this filing.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an option exercise and related stock sale. He exercised stock options covering 4,125 shares of common stock at $22.86 per share, then sold 5,500 shares in an open-market transaction at $78.71 per share.
Following these transactions, he directly holds 205,648 shares of common stock and retains stock options representing the right to purchase 118,915 shares, expiring on December 18, 2033. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, and represents a small portion of his overall holdings.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on May 13, 2026 at weighted average prices of about $82.05 and $82.58 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the sales, Henderson continues to hold over one million Apogee Therapeutics shares, so the transactions represent a small portion of his overall position.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises. On May 6, 2026, he completed open-market sales totaling 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share under a pre-arranged Rule 10b5-1 trading plan.
He also exercised 4,125 stock options at an exercise price of $22.86 per share, converting options into common stock. A related option grant covers 175,345 shares that vest in forty-eight equal monthly installments through December 18, 2027, conditioned on his continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson executed pre-planned open-market sales of company common stock. On May 1, 2026, she sold a total of 2,000 shares in three transactions at reported weighted average prices between about $81 and $83 per share, under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these sales, she directly holds 173,371 shares of Apogee common stock.
Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share. Following this exercise, he directly holds 1,135,987 shares of common stock.
The exercised options are part of a grant representing the right to purchase 398,512 shares, which vests in forty-eight equal monthly installments over four years, subject to his continued service. After this transaction, 387,012 options from this grant remain outstanding and are scheduled to expire on December 18, 2033.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported an open-market sale of 2,000 shares of common stock at $90.00 per share on April 16, 2026. Following this transaction, she directly holds 175,371 shares of Apogee common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson reported open-market sales of company common stock. On April 8, 2026, he sold 17,800 shares at a weighted average price of $82.48, 2,000 shares at $83.26, and 200 shares at $85.00.
These transactions were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025, indicating they were pre-scheduled. Following these sales, Henderson directly holds 1,132,987 shares of Apogee Therapeutics common stock.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options and sold shares in a planned transaction. He exercised options covering 4,125 shares of common stock at an exercise price of $22.86 per share and received 4,125 shares.
On the same date, he sold a total of 5,500 common shares in open-market trades at weighted average prices of about $84.31, $85.33, and $85.89, leaving him with 208,398 directly held shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. A related option grant represents the right to purchase 175,345 shares vesting monthly through December 18, 2027, subject to continued service.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported routine open-market stock sales under a pre-arranged Rule 10b5-1 trading plan. On April 1, 2026, she sold 900 shares of common stock at a weighted average price of $84.46 and 1,100 shares at a weighted average price of $85.46, across multiple trades within disclosed price ranges. After these sales, she held 177,371 shares of common stock directly.
Apogee Therapeutics’ Chief Financial Officer Jane Henderson reported an open‑market sale of 2,000 shares of common stock at $85.00 per share. The transaction took place on March 25, 2026. After this sale, she directly holds 179,371 shares of Apogee common stock.
According to a footnote, this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 2, 2025. Such plans allow insiders to sell shares according to a preset schedule, reducing the role of day‑to‑day discretion in timing.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on March 11, 2026 at weighted average prices reported as $74.29, $74.83, and $75.86 per share, across multiple trades within disclosed price ranges.
The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the reported sales, Henderson directly holds 1,152,987 shares of Apogee Therapeutics Common Stock, indicating he retains a large remaining equity position.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported option exercises and share sales. On March 4, 2026, he exercised stock options for 4,125 shares and acquired 4,125 shares of common stock at $22.86 per share. He then sold a total of 5,500 common shares in three open-market transactions at weighted average prices of $70.33, $71.98 and $73.26 per share, executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Following these trades, he held 209,773 shares of Apogee Therapeutics common stock directly.
Apogee Therapeutics Chief Financial Officer Jane Henderson reported selling 2,000 shares of Apogee Therapeutics common stock in a series of open-market transactions on March 2, 2026. The sales, coded as open-market transactions, occurred at weighted average prices of $68.27, $69.43, $70.45 and $71.66, with each price reflecting multiple trades within stated ranges. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 2, 2025. After the final sale, Henderson directly held 181,371 shares of Apogee Therapeutics common stock.
Apogee Therapeutics, Inc. chief executive Michael Thomas Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 11, 2026, he executed three open-market sales of Apogee common stock: 11,494 shares at a weighted average price of $62.96, 7,551 shares at $63.73, and 955 shares at $64.99.
The filing notes that these trades were made pursuant to a Rule 10b5-1 plan adopted on August 13, 2025, and that prices reflect weighted averages across multiple transactions within specified ranges. Following the last reported sale, Henderson directly beneficially owns 1,172,987 shares of Apogee common stock.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported an option exercise and related share sales. On 02/04/2026, he exercised stock options for 4,125 shares of common stock at an exercise price of $22.86 per share.
On the same date, he sold multiple small blocks of Apogee common stock at weighted average prices of $64.88, $65.83, $66.85, $67.88 and $68.94 per share, under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he directly held 211,148 shares of common stock and 135,415 derivative securities (stock options) of Apogee Therapeutics.
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported planned stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, she sold 792 shares of common stock at a weighted average price of $65.21, 1,108 shares at $66.15, and 100 shares at $66.89.
The weighted average prices reflect multiple trades in ranges from $64.80 to $65.61 and from $65.84 to $66.75. After these transactions, she directly owned 183,371 shares of Apogee common stock.
Apogee Therapeutics, Inc. insider filing shows a major share sale by an investment fund linked to company directors. Fairmount Healthcare Fund II L.P., managed by Fairmount Funds Management LLC, sold 1,750,000 shares of Apogee common stock on 01/22/2026 at $76.30 per share in an indirect transaction. After this sale, the fund is reported as indirectly holding 298,647 shares of common stock.
The filing also reports that Fairmount Healthcare Fund II L.P. indirectly holds 6,743,321 shares of non-voting common stock, which are convertible into Apogee common stock on a 1-for-1 basis, subject to a beneficial ownership cap of 9.99%, which can be increased to up to 19.99% with 61 days’ notice. Separately, director-affiliated individuals Tomas Kiselak and Peter Harwin are each shown as indirectly holding 51,166 shares of common stock. Fairmount, Kiselak, and Harwin disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Thomas Henderson reported open‑market sales of the company’s common stock. On January 14, 2026, he sold shares in multiple transactions at weighted average prices ranging from about $78.16 to $83.84 per share, under a pre‑arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following these sales, he reported beneficial ownership of 1,192,987 shares of Apogee common stock held directly.
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported several stock transactions in common shares and options. On January 7, 2026, he exercised a stock option for 14,025 shares of common stock at an exercise price of $22.86 per share, then sold shares in multiple trades: 2,954 shares at $77.13, 14,820 shares at $77.90, 826 shares at $79.04, and 100 shares at $80.06. The sales were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. After these transactions, he beneficially owned 212,523 shares of common stock and 139,540 stock options. The filing also notes that earlier Forms 4 since October 3, 2025 overstated his beneficial ownership by 53,910 shares due to an administrative error, and this report reflects the corrected amount.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski received a new stock option grant. On January 2, 2026, he was awarded an option to purchase 83,690 shares of Apogee Therapeutics common stock at an exercise price of $75.78 per share. The option was reported as held directly by the officer.
The option will vest in 48 equal monthly installments over four years from the grant date, as long as he continues providing service to the company. The option expires on January 2, 2036, and represents a long-term equity incentive rather than an immediate share purchase.
Apogee Therapeutics’ chief financial officer Jane Henderson reported stock sales and a new stock option grant. On January 2, 2026, she sold 1,920 shares of common stock at a weighted average price of $74.13 and 4,080 shares at a weighted average price of $75.20, under a Rule 10b5-1 trading plan adopted on September 27, 2024. On January 6, 2026, she sold an additional 2,000 shares at $80.00, leaving her with 185,371 common shares held directly.
Separately, on January 2, 2026, she received a stock option to purchase 83,690 shares of common stock at an exercise price of $75.78 per share. This option vests in 48 equal monthly installments over four years from the grant date, subject to her continued service, and is scheduled to expire on January 2, 2036.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Henderson reported insider sales of common stock. On December 10, 2025, he sold a total of 20,000 shares of Apogee common stock in three transactions at weighted-average prices of $74.88, $75.79, and $76.58 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
Following these sales, Henderson beneficially owns 1,212,987 shares of Apogee common stock directly. Some of the reported prices represent weighted averages for multiple trades executed within price ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share, and he has agreed to provide detailed trade information to Apogee, any shareholder, or the SEC upon request.
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a sale of company stock. On December 4, 2025, he sold 10,900 shares of Apogee Therapeutics common stock at a weighted average price of about $75 per share, through multiple transactions between $75.00 and $75.01. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024. After these sales, he directly beneficially owns 271,108 shares of Apogee Therapeutics common stock.
Apogee Therapeutics, Inc. (APGE) reported an insider stock sale by its Chief Financial Officer, who is a reporting officer of the company. On 11/14/2025, the officer sold 2,000 shares of common stock at a price of $65 per share, in a transaction coded as an "S" sale. After this transaction, the officer beneficially owned 197,871 shares of Apogee common stock in direct ownership form. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was adopted on September 27, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson. On 11/11/2025, she sold 1,000 shares of common stock at $60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024. Following the sale, she beneficially owns 199,871 shares, held directly.
Apogee Therapeutics (APGE) filed a Form 4 reporting insider sales by CEO and director Michael Henderson. On 11/13/2025, he sold a total of 20,000 shares in four transactions executed under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Weighted average prices were $61.93 (range $61.45–$62.39), $63.14 (range $62.50–$63.47), $63.89 (range $63.52–$64.39), and $64.52. Following these sales, Henderson directly beneficially owns 1,272,987 shares.